I型干扰素抑制剂anifrolumab治疗活动性系统性红斑狼疮(TULIP-1):一项随机对照3期试验
TULIP-1是一项双盲随机对照3期试验,纳入457例活动性SLE患者,比较anifrolumab 300mg与安慰剂。但BICLA应答、CLASI-50应答及口服激素减量等次要终点显示anifrolumab可能带来临床获益。
要点
- 主要终点SRI-4应答率anifrolumab 300mg组36% vs 安慰剂组40%,差异无统计学意义。
- 基线CLASI≥10患者中,第12周CLASI-50应答率anifrolumab组42% vs 安慰剂组25%。
核心结论
- TULIP-1未达到主要终点SRI-4应答,但BICLA应答、CLASI应答和口服激素减量等次要终点提示anifrolumab相比安慰剂可能具有临床获益。
研究设计与样本
- TULIP-1为双盲、随机、对照3期试验,在18个国家123个中心开展,纳入18-70岁中度至重度活动性SLE且接受稳定标准治疗的患者。
- 457例患者按2:1:2随机接受安慰剂、anifrolumab 150mg或300mg静脉给药每4周一次共48周,主要终点为第52周SRI-4应答率(300mg vs 安慰剂)。
主要发现
- 严重不良事件发生率anifrolumab 300mg组14%(25/180)、150mg组11%(10/93)、安慰剂组16%(30/184),安全性与2期试验相似。
关键数值与推荐
- 主要终点为第52周SRI-4应答率(anifrolumab 300mg vs 安慰剂)。
临床怎么用
- 尽管主要终点未达到,anifrolumab在BICLA应答、皮肤活动度改善和激素减量方面显示出潜在获益,可能为接受标准治疗仍有活动性SLE的患者提供治疗选择。
- 需等待进一步3期试验数据以确认anifrolumab的疗效。
局限性
- 主要终点未达到,疗效证据尚不确凿。
- 1年3期试验存在固有局限性,包括对一般人群适用性认识不完整、罕见安全性信号检出有限,以及预设限制用药规则带来的复杂性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type I interferons are involved in systemic lupus erythematosus (SLE) pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1, suppressed interferon gene signatures and substantially reduced SLE disease activity. Here, we sought to confirm the efficacy of anifrolumab versus placebo in a phase 3 trial of adult patients with SLE and moderate-to-severe disease activity despite standard-of-care treatment. METHODS: TULIP-1 was a double-blind, randomised, controlled, phase 3 trial done at 123 sites in 18 countries. Included patients were aged 18-70 years, with moderate-to-severe SLE, and ongoing stable treatment with either prednisone or equivalent, an antimalarial, azathioprine, mizoribine, mycophenolate mofetil or mycophenolic acid, or methotrexate. Patients were randomly assigned (2:1:2) to receive placebo, anifrolumab 150 mg, or anifrolumab 300 mg intravenously every 4 weeks for 48 weeks. Stable standard-of-care treatment continued except for mandatory attempts at oral corticosteroid tapering for patients receiving prednisone or equivalent of 10 mg/day or more at baseline. The primary outcome was the difference between the proportion of patients who achieved an SLE responder index-4 (SRI-4) response at week 52 with anifrolumab 300 mg versus with placebo. Key secondary outcomes were the difference between the anifrolumab 300 mg group and the placebo group in: proportion of patients in the interferon gene signature test-high subgroup who achieved SRI-4 at week 52; proportion of patients on 10 mg/day or more corticosteroids at baseline who achieved a sustained dose reduction to 7·5 mg/day or less from week 40 to 52; proportion of patients with a cutaneous lupus erythematosus disease area and severity index (CLASI) activity score of 10 or higher at baseline who achieved a 50% or more reduction in CLASI score by week 12; proportion of patients who achieved SRI-4 at week 24; and annualised flare rate through week 52. Other measures of disease activity were also assessed at week 52, including the British Isles Lupus Assessment Group-based composite lupus assessment (BICLA). Safety was also assessed. Efficacy and safety analyses were done in the population of patients who received at least one dose of study drug. This trial was registered at ClinicalTrials.gov (NCT02446912). FINDINGS: Between June 9, 2015, and June 16, 2017, 457 patients were randomly assigned to the anifrolumab 300 mg group (n=180), the anifrolumab 150 mg group (n=93), or the placebo group (n=184). The proportion of patients at week 52 with an SRI-4 response was similar between anifrolumab 300 mg (65 [36%] of 180) and placebo (74 [40%] of 184; difference -4·2 [95% CI -14·2 to 5·8], p=0·41). Similarly, proportions of patients with an SRI-4 response at week 24, and at week 52 in patients in the interferon gene signature test-high subgroup, did not differ between the anifrolumab and placebo groups. In patients with baseline oral corticosteroids of at least 10 mg/day, sustained dose reduction to 7·5 mg/day or less was achieved by 42 (41%) of 103 patients in the anifrolumab 300 mg group and 33 (32%) of 102 patients in the placebo group (difference 8·9 [95% CI -4·1 to 21·9]). In patients with CLASI activity score of at least 10 at baseline, at least 50% reduction by week 12 was achieved by 24 (42%) of 58 patients in the anifrolumab 300 mg group and 14 (25%) of 54 in the placebo group (difference 17·0 [95% CI -0·3 to 34·3]). Annualised flare rates were 0·60 for anifrolumab and 0·72 for placebo (rate ratio 0·83 [95% CI 0·60 to 1·14]). BICLA response was achieved by 67 (37%) of 180 patients receiving anifrolumab 300 mg versus 49 (27%) of 184 receiving placebo (difference 10·1 [95% CI 0·6 to 19·7]). Anifrolumab's safety profile was similar to that observed in phase 2, with similar proportions of patients having a serious adverse event between groups (25 [14%] of 180 for anifrolumab 300 mg, ten [11%] of 93 for anifrolumab 150 mg, and 30 [16%] of 184 for placebo). INTERPRETATION: The primary endpoint was not reached. However, several secondary endpoints, including reduction in oral corticosteroid dose, CLASI responses, and BICLA responses, suggest clinical benefit of anifrolumab compared with placebo. Conclusive evidence for the efficacy of anifrolumab awaits further phase 3 trial data. Despite the inherent limitations of a 1-year phase 3 study, such as incomplete knowledge of applicability to the general population and scarce detection of rare safety signals, in addition to complications from prespecified restricted medication rules, our results suggest that anifrolumab might have the potential to provide a treatment option for patients who have active SLE while receiving standard therapy. FUNDING: AstraZeneca.
引用
- Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019. PMID: 38229377. doi:10.1016/S2665-9913(19)30076-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。